132810-10-7 | Blonanserin

Packsize	Purity	Availability	Price	Discounted Price
25mg	>98.0%(HPLC)	in stock	$36.00	$25.00
100mg	99%(HPLC)	in stock	$139.00	$97.00
250mg	99%(HPLC)	in stock	$323.00	$226.00
1g	≥ 98% (HPLC)	in stock	$1,162.00	$813.00

Description

• Catalog Number: AA48031
• Chemical Name: Blonanserin
• CAS Number: 132810-10-7
• Molecular Formula: C23H30FN3
• Molecular Weight: 367.5028
• MDL Number: MFCD00893838
• SMILES: CCN1CCN(CC1)c1nc2CCCCCCc2c(c1)c1ccc(cc1)F

Computed Properties

• Complexity: 443
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 27
• Hydrogen Bond Acceptor Count: 4
• Rotatable Bond Count: 3
• XLogP3: 5.5

Literature

• Newer antipsychotics and upcoming molecules for schizophrenia.

  European journal of clinical pharmacology 20130801

• Population pharmacokinetics of blonanserin in Chinese healthy volunteers and the effect of the food intake.

  Human psychopharmacology 20130301

• Blonanserin, a novel atypical antipsychotic agent not actively transported as substrate by P-glycoprotein.

  Progress in neuro-psychopharmacology & biological psychiatry 20121001

• Quetiapine-induced insulin resistance after switching from blonanserin despite a loss in both bodyweight and waist circumference.

  Psychiatry and clinical neurosciences 20121001

• Development and validation of a stability-indicating gas chromatographic method for quality control of residual solvents in blonanserin: a novel atypical antipsychotic agent.

  Journal of chromatographic science 20120901

• Simultaneous determination of blonanserin and its metabolite in human plasma and urine by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120815

• Improvement in quetiapine-induced hypoglycemia following a switch to blonanserin.

  Psychiatry and clinical neurosciences 20120601

• The relationship between the plasma concentration of blonanserin, and its plasma anti-serotonin 5-HT(2A) activity/anti-dopamine D₂ activity ratio and drug-induced extrapyramidal symptoms.

  Psychiatry and clinical neurosciences 20120301

• Effect of blonanserin on cognitive function in antipsychotic-naïve first-episode schizophrenia.

  Human psychopharmacology 20120101

• Association of typical versus atypical antipsychotics with symptoms and quality of life in schizophrenia.

  PloS one 20120101

• Role of aripiprazole in treatment-resistant schizophrenia.

  Neuropsychiatric disease and treatment 20120101

• Functional potencies of dopamine agonists and antagonists at human dopamine D₂ and D₃ receptors.

  European journal of pharmacology 20110901

• Blonanserin in the treatment of delirium.

  Psychiatry and clinical neurosciences 20110601

• Three cases of schizophrenia showing improvement after switching to blonanserin.

  Psychiatry and clinical neurosciences 20110601

• Olfactory reference syndrome treated by blonanserin augmentation.

  Psychiatry and clinical neurosciences 20110301

• Effect of novel atypical antipsychotic, blonanserin, on extracellular neurotransmitter level in rat prefrontal cortex.

  European journal of pharmacology 20110225

• Neuroleptic malignant syndrome induced by blonanserin.

  The Journal of neuropsychiatry and clinical neurosciences 20110101

• Comparative study of treatment continuation using second-generation antipsychotics in patients with schizophrenia or schizoaffective disorder.

  Neuropsychiatric disease and treatment 20110101

• Systematic drug repositioning based on clinical side-effects.

  PloS one 20110101

• A case control association study and cognitive function analysis of neuropilin and tolloid-like 1 gene and schizophrenia in the Japanese population.

  PloS one 20110101

• Five Alzheimer's disease cases with refractory behavioural psychological symptoms of dementia treated with blonanserin.

  Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society 20101201

• Adjunctive treatment with low-dosage aripiprazole for blonanserin-induced hyperprolactinemia in a female patient with schizophrenia.

  Progress in neuro-psychopharmacology & biological psychiatry 20101001

• Case of delirium complicated with pneumonia that improved with blonanserin administration.

  Psychiatry and clinical neurosciences 20101001

• Effect of dose timing in relation to food intake on systemic exposure to blonanserin.

  European journal of clinical pharmacology 20100901

• Atypical antipsychotic properties of blonanserin, a novel dopamine D2 and 5-HT2A antagonist.

  Pharmacology, biochemistry, and behavior 20100801

• Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial.

  Clinical neuropharmacology 20100701

• Blonanserin: a review of its use in the management of schizophrenia.

  CNS drugs 20100101

• Fluvoxamine for blonanserin-associated akathisia in patients with schizophrenia: report of five cases.

  Annals of general psychiatry 20100101

• Beneficial effects of loxapine on agitation and breathing patterns during weaning from mechanical ventilation.

  Critical care (London, England) 20100101

• The relationship between the daily dose, the plasma concentration of blonanserin, and its plasma anti-dopamine D2 and anti-serotonin 5-HT2A activity.

  Human psychopharmacology 20100101

• Sensitive analysis of blonanserin, a novel antipsychotic agent, in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry.

  Analytical sciences : the international journal of the Japan Society for Analytical Chemistry 20100101

• Efficacy of blonanserin in combination therapy for treatment-resistant depression.

  Psychiatry and clinical neurosciences 20090801

• The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study.

  CNS drugs 20090101

• [Pharmacological profiles and clinical effects of blonanserin (Lonasen) on schizophrenia].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20081201

• Syntheses and properties of the major hydroxy metabolites in humans of blonanserin AD-5423, a novel antipsychotic agent.

  Bioorganic & medicinal chemistry letters 20050215

• Atypical properties of several classes of antipsychotic drugs on the basis of differential induction of Fos-like immunoreactivity in the rat brain.

  Life sciences 20041126

• Effect of AD-5423 on animal models of schizophrenia: phencyclidine-induced behavioral changes in mice.

  Neuroreport 20030210

• Crystal structure of an antipsychotic agent, 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine (blonanserin).

  Analytical sciences : the international journal of the Japan Society for Analytical Chemistry 20021101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20021101

• The effects of neuroleptics on the GABA-induced Cl- current in rat dorsal root ganglion neurons: differences between some neuroleptics.

  British journal of pharmacology 20020301

• Blonanserin. AD 5423.

  Drugs in R&D 20020101

• Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties.

  The Journal of pharmacology and experimental therapeutics 19930101